Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FUCA1 | P04066 | 2/20 | 0.49 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.46 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 2/20 | 0.45 |
| ▸ | MC4R | P32245 | 1/20 | 0.43 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.43 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | BCHE | P06276 | 1/20 | 0.42 |
| ▸ | BACE1 | P56817 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3210015 | 0.84 | ACHE (0.47) | FUCA1SIGMAR1CXCR4ACHEBCHE | |
| SCHEMBL5105700 | 0.84 | NPY5R (0.46) | FUCA1NPY5RSIGMAR1CXCR4ACHE | |
| SCHEMBL25933663 | 0.81 | FUCA1 (0.53) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL12723223 | 0.81 | FUCA1 (0.53) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL16775256 | 0.80 | FUCA1 (0.64) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL16759827 | 0.80 | FUCA1 (0.64) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL1014404 | 0.80 | S1PR5 (0.50) | FUCA1NPY5RSIGMAR1S1PR1S1PR5 | |
| SCHEMBL13102792 | 0.79 | FUCA1 (0.51) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL4619365 | 0.79 | FUCA1 (0.51) | FUCA1SIGMAR1ACHEMC4RS1PR1 | |
| SCHEMBL19023828 | 0.79 | FUCA1 (0.55) | FUCA1SIGMAR1ACHEMC4RS1PR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070021487-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2007-01-25 | — | — | US | disclosed |
| EP-1626957-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | Ranbaxy Laboratories Limited (IN) | 2006-02-22 | — | — | EP | disclosed |
| WO-2004089900-A1 | AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021487-A1 | Azabicyclo derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | FUCA1 2518/4885NPY5R 363/4885SIGMAR1 620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.